NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis $8.00 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.00▼$8.0050-Day Range$7.70▼$9.2052-Week Range$5.00▼$27.90Volume30 shsAverage Volume1,479 shsMarket Capitalization$8.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Addex Therapeutics alerts: Email Address Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Addex Therapeutics Stock (NASDAQ:ADXN)Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Read More ADXN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADXN Stock News HeadlinesJuly 24 at 4:23 AM | sg.finance.yahoo.comAddex Therapeutics Ltd (APE1.MU)July 22, 2024 | finanznachrichten.deAddex Therapeutics: Addex's Partner Discontinues ADX71149 development in EpilepsyJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 22, 2024 | finanznachrichten.deAddex Therapeutics: Addex's Partner Janssen Pharma Discontinues ADX71149 development in EpilepsyJuly 22, 2024 | globenewswire.comAddex's Partner Discontinues ADX71149 development in EpilepsyJuly 15, 2024 | globenewswire.comAddex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)July 12, 2024 | globenewswire.comAddex To Present at the Thirteenth London International Cough Symposium (13th LICS)July 1, 2024 | globenewswire.comAddex Shareholders Approve All Resolutions at Annual General MeetingJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 6, 2024 | investorplace.comADXN Stock Earnings: Addex Therapeutics Reported Results for Q1 2024June 6, 2024 | globenewswire.comAddex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate UpdateJune 5, 2024 | globenewswire.comAddex Convenes Annual General Meeting 2024May 31, 2024 | globenewswire.comAddex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024May 8, 2024 | globenewswire.comAddex to Present at Bio€quity Europe 2024May 8, 2024 | morningstar.comAddex Therapeutics Ltd ADR ADXNApril 29, 2024 | msn.comTech Rally Subsides as US Equity Futures Waver Pre-BellApril 29, 2024 | msn.comAddex stock plunges 50% on failed study for epilepsy drugApril 29, 2024 | finanznachrichten.deAddex Therapeutics: Addex Provides Update on ADX71149 Phase 2 Epilepsy StudySee More Headlines Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/06/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADXN CUSIPN/A CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,760,000.00 Net Margins-818.50% Pretax Margin-644.62% Return on Equity-364.24% Return on Assets-154.26% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$1.83 million Price / Sales4.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.20 per share Price / Book6.67Miscellaneous Outstanding Shares1,060,000Free Float901,000Market Cap$8.48 million OptionableNot Optionable Beta1.77 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Timothy Mark Dyer (Age 56)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 67)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 38)Head of Finance Dr. Mikhail Kalinichev Ph.D. (Age 57)Head of Translational Science Key CompetitorsLipocineNASDAQ:LPCNAkari TherapeuticsNASDAQ:AKTXEquilliumNASDAQ:EQDaré BioscienceNASDAQ:DAREVYNE TherapeuticsNASDAQ:VYNEView All Competitors ADXN Stock Analysis - Frequently Asked Questions How have ADXN shares performed this year? Addex Therapeutics' stock was trading at $6.05 at the beginning of the year. Since then, ADXN stock has increased by 32.2% and is now trading at $8.00. View the best growth stocks for 2024 here. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd (NASDAQ:ADXN) announced its earnings results on Thursday, June, 6th. The company reported ($1.37) earnings per share for the quarter. The company earned $0.27 million during the quarter. Addex Therapeutics had a negative trailing twelve-month return on equity of 364.24% and a negative net margin of 818.50%. When did Addex Therapeutics' stock split? Addex Therapeutics shares reverse split on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT) and Abiomed (ABMD). This page (NASDAQ:ADXN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
